Developer docs
API playgroundTry for free, no card

Search company profiles

Medpace

Full company profile

uuid0002le7

Namestring
Medpace
Legal namestring
Medpace, Inc.
Websiteurl
medpace.com
Company typeenum
Public
Founded yearint
1992
Descriptiontext

Medpace, Inc. is a publicly traded (NASDAQ: MEDP), full-service Contract Research Organization (CRO) founded in 1992 by August Troendle, MD, and headquartered in Cincinnati, Ohio. The company provides end-to-end clinical development services for pharmaceutical and biotechnology sponsors across preclinical through Phase IV studies, with documented therapeutic depth in oncology, cardiovascular, metabolic, neuroscience, rare diseases, cell and gene therapy, and several specialty areas. Medpace's service model is anchored by a proprietary integrated technology platform — ClinTrak — which unifies clinical trial management, EDC, IRT, ECG, imaging, and lab information management, and is supplemented by patient-facing tools (TrialPACE, OnPACE), feasibility/analytics modules (IntelliPACE, ClinTrak Data Explorer), and recruitment methodology (ExcelliPACE).

Underpinning the technology platform are wholly-owned central laboratories in Cincinnati, Belgium, Shanghai, and Singapore; a Bioanalytical Lab; Imaging Core Lab and Cardiovascular/ECG Core Lab; a Phase I clinical pharmacology unit; and wearable biosensor capabilities. Medpace operates across 46 countries with regional subsidiaries spanning North America, EMEA, Asia-Pacific, and Latin America, supported by a workforce of approximately 5,200–6,200 employees.

Commercially, Medpace targets primarily small-to-mid-sized biotech and biopharma sponsors, distributing services exclusively through direct, consultative enterprise sales under fixed-price, milestone-based multi-year contracts. Revenue is recognized over time as services are rendered. FY2025 revenue was $2.53 billion with net income of $451.1 million; Q1 2026 revenue grew 26.5% year-over-year to $706.6 million, with FY2026 guidance of $2.755–$2.855 billion. The company has grown exclusively through organic expansion over more than 30 years, avoiding the M&A activity common among peers.

Short descriptiontext

Medpace is a publicly traded, full-service Contract Research Organization (CRO) providing end-to-end clinical development services — anchored by its proprietary ClinTrak platform and wholly-owned central labs — primarily to small-to-mid-sized biotech and biopharma sponsors globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersCincinnati, United States
HQ citystring
Cincinnati
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research organization, contract research services, drug development services, central laboratory services, biopharmaceutical CRO
Industry7 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Other Scientific and Technical Consulting Services54169
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (CRO) Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

Medpace generates the vast majority of its revenue through fixed-price, project-based contracts for clinical research services spanning preclinical through Phase IV. Revenue is recognized over time as services are rendered, with contracts typically structured as standalone performance obligations tied to specific milestones or deliverable phases. Upsell and expansion occur as sponsors advance drugs through additional trial phases or add therapeutic area programs.

Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom project-based contracts negotiated per sponsor engagement
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is not publicly disclosed. Contracts are typically structured as fixed-price, milestone-based agreements with duration and scope determining overall contract value. Quotes are provided on a per-project basis following business development discussions.

GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1ClinTrak
Description

Proprietary clinical trial management system (CTMS) platform used for study management, data capture, and operational oversight.

medpace.com
+4 more records
Core offering1 text field

Medpace is a global full-service Contract Research Organization (CRO) that provides end-to-end clinical development services for pharmaceutical and biotechnology sponsors across preclinical through Phase IV. Its offerings are anchored by the proprietary ClinTrak technology platform and supported by wholly-owned Central Laboratories, Bioanalytical Lab, Imaging Core Lab, Cardiovascular & ECG Core Lab, and a Phase I Unit, delivering study start-up, clinical trial management, monitoring, regulatory affairs, biostatistics, pharmacovigilance, medical writing, and quality assurance through a single-vendor outsourcing model.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Q1 2026 revenue of $706.6 million representing 26.5% year-over-year growth, indicating strong customer demand and execution
+2 more records
Product overview1 text field

Medpace is a global full-service Contract Research Organization (CRO) providing end-to-end drug and medical device development services, primarily serving small and mid-sized biopharma companies. The company's core offering is anchored by its proprietary ClinTrak technology platform, an integrated Clinical Trial Management System that unifies study management, EDC, IRT, ECG, imaging, and lab modules, supplemented by patient-facing tools (TrialPACE, OnPACE) and analytics (ClinTrak Data Explorer). Supporting the platform are wholly-owned, integrated service units: Central Laboratories, Bioanalytical Laboratory, Imaging Core Laboratory, Cardiovascular & ECG Core Laboratory, and a Phase I Unit. The full breadth of CRO services — regulatory affairs, clinical trial management, clinical monitoring, biostatistics, pharmacovigilance, medical writing, quality assurance, patient recruitment, and clinical packaging — is delivered through a therapeutically-focused, single-vendor model, with therapeutic depth across oncology, cardiovascular, rare diseases, cell and gene therapy, and other specialty areas.

Product and service1 record
1Full-Service CRO
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeGTM or Marketing Partner
Description

Medpace maintains an active partnership with SCRS, a leading global organization representing clinical research sites. The relationship involves ongoing collaboration to support site sustainability, advance site-CRO relationships, and participate in industry advocacy initiatives. Medpace's recognition with the SCRS Eagle Award reflects the depth of this engagement.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

IQVIA is the largest global CRO and life sciences technology provider, offering full-service clinical development alongside real-world data and analytics. It competes directly with Medpace for biotech sponsor engagements but operates at a much broader scale across the entire life sciences value chain.

TypeDirect peer
Description

ICON is a global full-service CRO formed via the PRA Health Sciences merger, serving biotech and pharma sponsors across all clinical phases. Head-to-head competitor to Medpace for biotech clinical trial outsourcing, particularly in oncology and rare disease.

TypeBroad incumbent
Description

Thermo Fisher acquired PPD to build a leading global clinical development services franchise. As a large diversified life sciences platform, PPD competes with Medpace for biotech clinical trials while offering broader analytical instruments and pharma services breadth.

TypeDirect peer
Description

PSI CRO is a privately-held full-service CRO with strong biotech sponsor coverage across oncology, rare disease, and other specialty areas. It competes directly with Medpace for full-service clinical trial outsourcing engagements from mid-sized biotechs.

TypeBroad incumbent
Description

Charles River provides preclinical and clinical CRO services plus manufacturing solutions to biotech and pharma. While its core is preclinical, its clinical services and biologics capabilities overlap with Medpace's drug development offerings for emerging sponsors.

TypeDirect peer
Description

Parexel is a global full-service CRO with strong biotech and mid-market sponsor coverage, owned by EQT/Goldman Sachs Asset Management. It competes directly with Medpace for full-service clinical development work across therapeutic areas.

TypeRegional player
Description

WuXi AppTec is a leading China-based CRO/CDMO offering preclinical, clinical, and bioanalytical services globally. It is a comparable full-service clinical CRO, though recent US BIOSECURE legislation has constrained its ability to serve US biotech sponsors — a dynamic relevant to Medpace's competitive positioning.

TypeDirect peer
Description

Worldwide Clinical Trials is a mid-sized full-service CRO focused on complex therapeutic areas including CNS, oncology, and rare diseases. It competes with Medpace for mid-sized biotech sponsor work and shares a similar scientific-focus positioning.

TypeDirect peer
Description

Syneos Health is a full-service biopharmaceutical solutions organization covering clinical and commercial services, with strong biotech sponsor relationships. Now privately held after Elliott/Veritas-led take-private, it competes directly with Medpace on clinical trial outsourcing.

TypeBroad incumbent
Description

Labcorp owns central lab services and spun out Fortrea as the clinical CRO business. Both arms overlap with Medpace's central lab and full-service CRO offerings, and Labcorp/Fortrea are frequent bidders against Medpace on biotech programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries8 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medpace

Contract Research Organization (CRO) Servicesmedpace.com

Medpace is a publicly traded, full-service Contract Research Organization (CRO) providing end-to-end clinical development services — anchored by its proprietary ClinTrak platform and wholly-owned central labs — primarily to small-to-mid-sized biotech and biopharma sponsors globally.

What Medpace does

Medpace, Inc. is a publicly traded (NASDAQ: MEDP), full-service Contract Research Organization (CRO) founded in 1992 by August Troendle, MD, and headquartered in Cincinnati, Ohio. The company provides end-to-end clinical development services for pharmaceutical and biotechnology sponsors across preclinical through Phase IV studies, with documented therapeutic depth in oncology, cardiovascular, metabolic, neuroscience, rare diseases, cell and gene therapy, and several specialty areas. Medpace's service model is anchored by a proprietary integrated technology platform — ClinTrak — which unifies clinical trial management, EDC, IRT, ECG, imaging, and lab information management, and is supplemented by patient-facing tools (TrialPACE, OnPACE), feasibility/analytics modules (IntelliPACE, ClinTrak Data Explorer), and recruitment methodology (ExcelliPACE).

Underpinning the technology platform are wholly-owned central laboratories in Cincinnati, Belgium, Shanghai, and Singapore; a Bioanalytical Lab; Imaging Core Lab and Cardiovascular/ECG Core Lab; a Phase I clinical pharmacology unit; and wearable biosensor capabilities. Medpace operates across 46 countries with regional subsidiaries spanning North America, EMEA, Asia-Pacific, and Latin America, supported by a workforce of approximately 5,200–6,200 employees.

Commercially, Medpace targets primarily small-to-mid-sized biotech and biopharma sponsors, distributing services exclusively through direct, consultative enterprise sales under fixed-price, milestone-based multi-year contracts. Revenue is recognized over time as services are rendered. FY2025 revenue was $2.53 billion with net income of $451.1 million; Q1 2026 revenue grew 26.5% year-over-year to $706.6 million, with FY2026 guidance of $2.755–$2.855 billion. The company has grown exclusively through organic expansion over more than 30 years, avoiding the M&A activity common among peers.

Medpace firmographics

Firmographics
Name
Medpace
Legal name
Medpace, Inc.
Website
https://medpace.com
Company type
Public
Founded year
1992
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
Medpace is a publicly traded, full-service Contract Research Organization (CRO) providing end-to-end clinical development services — anchored by its proprietary ClinTrak platform and wholly-owned central labs — primarily to small-to-mid-sized biotech and biopharma sponsors globally.
Ownership category
akta.pro rank

Medpace industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Other Scientific and Technical Consulting Services (54169)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Clinical research organization
  • Contract research services
  • Drug development services
  • Central laboratory services
  • Biopharmaceutical CRO

Where Medpace is headquartered

Location

Headquarters

HQ city
Cincinnati
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Medpace business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: Medpace generates the vast majority of its revenue through fixed-price, project-based contracts for clinical research services spanning preclinical through Phase IV. Revenue is recognized over time as services are rendered, with contracts typically structured as standalone performance obligations tied to specific milestones or deliverable phases. Upsell and expansion occur as sponsors advance drugs through additional trial phases or add therapeutic area programs.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based contracts negotiated per sponsor engagement

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Medpace product offering

Product offering

Core offering

Medpace is a global full-service Contract Research Organization (CRO) that provides end-to-end clinical development services for pharmaceutical and biotechnology sponsors across preclinical through Phase IV. Its offerings are anchored by the proprietary ClinTrak technology platform and supported by wholly-owned Central Laboratories, Bioanalytical Lab, Imaging Core Lab, Cardiovascular & ECG Core Lab, and a Phase I Unit, delivering study start-up, clinical trial management, monitoring, regulatory affairs, biostatistics, pharmacovigilance, medical writing, and quality assurance through a single-vendor outsourcing model.

Product overview

Medpace is a global full-service Contract Research Organization (CRO) providing end-to-end drug and medical device development services, primarily serving small and mid-sized biopharma companies. The company's core offering is anchored by its proprietary ClinTrak technology platform, an integrated Clinical Trial Management System that unifies study management, EDC, IRT, ECG, imaging, and lab modules, supplemented by patient-facing tools (TrialPACE, OnPACE) and analytics (ClinTrak Data Explorer). Supporting the platform are wholly-owned, integrated service units: Central Laboratories, Bioanalytical Laboratory, Imaging Core Laboratory, Cardiovascular & ECG Core Laboratory, and a Phase I Unit. The full breadth of CRO services — regulatory affairs, clinical trial management, clinical monitoring, biostatistics, pharmacovigilance, medical writing, quality assurance, patient recruitment, and clinical packaging — is delivered through a therapeutically-focused, single-vendor model, with therapeutic depth across oncology, cardiovascular, rare diseases, cell and gene therapy, and other specialty areas.

Differentiator

Problem solved

Functional benefit

Brands

  • ClinTrak: Proprietary clinical trial management system (CTMS) platform used for study management, data capture, and operational oversight.
  • TrialPACE
  • IntelliPACE
  • ExcelliPACE
  • Trusted by Biotech

Products and services

  • Full-Service CRO

Quantifiable outcome

  • Q1 2026 revenue of $706.6 million representing 26.5% year-over-year growth, indicating strong customer demand and execution
  • +2 more outcomes

Companies that use Medpace

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Medpace technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Medpace partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Society for Clinical Research Sites (SCRS)coreGTM or Marketing PartnerMedpace maintains an active partnership with SCRS, a leading global organization representing clinical research sites. The relationship involves ongoing collaboration to support site sustainability, advance site-CRO relationships, and participate in industry advocacy initiatives. Medpace's recognition with the SCRS Eagle Award reflects the depth of this engagement.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Medpace competitors and assessment

Company assessment

Broad incumbents

  • IQVIA Holdings: IQVIA is the largest global CRO and life sciences technology provider, offering full-service clinical development alongside real-world data and analytics. It competes directly with Medpace for biotech sponsor engagements but operates at a much broader scale across the entire life sciences value chain.
  • Thermo Fisher Scientific (PPD): Thermo Fisher acquired PPD to build a leading global clinical development services franchise. As a large diversified life sciences platform, PPD competes with Medpace for biotech clinical trials while offering broader analytical instruments and pharma services breadth.
  • Charles River Laboratories: Charles River provides preclinical and clinical CRO services plus manufacturing solutions to biotech and pharma. While its core is preclinical, its clinical services and biologics capabilities overlap with Medpace's drug development offerings for emerging sponsors.
  • Labcorp (incl. Fortrea): Labcorp owns central lab services and spun out Fortrea as the clinical CRO business. Both arms overlap with Medpace's central lab and full-service CRO offerings, and Labcorp/Fortrea are frequent bidders against Medpace on biotech programs.

Direct peers

  • ICON plc: ICON is a global full-service CRO formed via the PRA Health Sciences merger, serving biotech and pharma sponsors across all clinical phases. Head-to-head competitor to Medpace for biotech clinical trial outsourcing, particularly in oncology and rare disease.
  • PSI CRO: PSI CRO is a privately-held full-service CRO with strong biotech sponsor coverage across oncology, rare disease, and other specialty areas. It competes directly with Medpace for full-service clinical trial outsourcing engagements from mid-sized biotechs.
  • Parexel International: Parexel is a global full-service CRO with strong biotech and mid-market sponsor coverage, owned by EQT/Goldman Sachs Asset Management. It competes directly with Medpace for full-service clinical development work across therapeutic areas.
  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized full-service CRO focused on complex therapeutic areas including CNS, oncology, and rare diseases. It competes with Medpace for mid-sized biotech sponsor work and shares a similar scientific-focus positioning.
  • Syneos Health: Syneos Health is a full-service biopharmaceutical solutions organization covering clinical and commercial services, with strong biotech sponsor relationships. Now privately held after Elliott/Veritas-led take-private, it competes directly with Medpace on clinical trial outsourcing.

Regional players

  • WuXi AppTec: WuXi AppTec is a leading China-based CRO/CDMO offering preclinical, clinical, and bioanalytical services globally. It is a comparable full-service clinical CRO, though recent US BIOSECURE legislation has constrained its ability to serve US biotech sponsors — a dynamic relevant to Medpace's competitive positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Medpace social profiles

Digital presence

Medpace financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medpace leadership team

Management profile

Number of profiles

Profiles13 records

Medpace subsidiaries and ownership

Company hierarchy

Subsidiaries8 records

Medpace funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medpace M&A and investment

M&A and investment

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medpace

What does Medpace do?

Medpace is a global full-service Contract Research Organization (CRO) that provides end-to-end clinical development services for pharmaceutical and biotechnology sponsors across preclinical through Phase IV. Its offerings are anchored by the proprietary ClinTrak technology platform and supported by wholly-owned Central Laboratories, Bioanalytical Lab, Imaging Core Lab, Cardiovascular & ECG Core Lab, and a Phase I Unit, delivering study start-up, clinical trial management, monitoring, regulatory affairs, biostatistics, pharmacovigilance, medical writing, and quality assurance through a single-vendor outsourcing model.

Is Medpace a public or private company?

Medpace is a public company. It is classified as public and is currently operating.

When was Medpace founded?

Medpace was founded in 1992. It employs 5,001 to 10,000 people.

Where is Medpace based?

Medpace is headquartered in Cincinnati, United States, in the North America region.

How does Medpace make money?

One revenue line is on record: contract Research Services.

Who are Medpace's main competitors?

Broad incumbents on record are IQVIA Holdings, Thermo Fisher Scientific (PPD), Charles River Laboratories and Labcorp (incl. Fortrea). Direct peers are ICON plc, PSI CRO, Parexel International, Worldwide Clinical Trials and Syneos Health. WuXi AppTec is listed as a regional player.

Does Medpace have an API?

No public API is recorded for Medpace.

What industry is Medpace in?

Medpace's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAI, Patient Recruitment, Site Feasibility & Trial Enablement CROs. Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Yahoo3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)Medpace is recommended as a growth stock with a favorable Growth Score and top Zacks Rank. Its EPS is projected to grow 18.2% this year, beating the industry average of 14%, and cash flow growth is 10.5% versus the industry's -1.4%.Business & FinancialEarly Phase Clinical Trial Outsourcing Market Report 2026 Capitalize On $14.8 Billion By 2030 Featuring Profiles Of Key Players IQVIA, ICON, Parexel And MedpaceThe global early phase clinical trial outsourcing market is projected to grow from $9.53 billion in 2025 to $14.8 billion by 2030, a CAGR of 9.2%. Growth is driven by personalized medicine, decentralized trials, and AI analytics, with key players including IQVIA, ICON, Parexel, and Medpace.Defense WorldMedpace Holdings, Inc. $MEDP Stock Sold by CenterBook Partners LPCenterBook Partners LP reduced its Medpace stake by 31.1% in Q3, selling 1,512 shares and holding 3,349 shares worth $2.09 million. Insiders sold 337,113 shares over 90 days, and analysts rate the stock a Hold with an average price target of $649.27.American Banking and Market NewsMedpace Holdings, Inc. $MEDP Shares Sold by CenterBook Partners LPCenterBook Partners LP reduced its Medpace stake by 31.1% in Q3, selling 1,512 shares. Analysts have an average "Hold" rating with a $649.27 price target, and the company reported Q3 EPS of $4.84, beating estimates.American Banking and Market NewsMedpace Holdings, Inc. $MEDP Shares Newly Acquired by Calamos Advisors LLCCalamos Advisors acquired a new stake in Medpace Holdings, buying 3,874 shares valued at about $2.4 million in Q3. Analysts have an average "Hold" rating with a price target of $649.27, and the stock opened at $653.11. Medpace reported Q3 EPS of $4.84, beating estimates.Simply Wall StEarnings Beat Might Change The Case For Investing In Medpace Stock (MEDP)Medpace Holdings reported Q3 2026 results that beat earnings and revenue expectations, supported by record awards and a larger pipeline. Analysts project earnings of $663.8 million and revenue of $3.4 billion by 2029, with a potential 12% upside from current price.Simply Wall StIs Medpace Holdings (MEDP) Priced For Perfection On Cash Flow?Medpace Holdings' stock closed at $656.77, with a 5-year total return of 197.2%. Its latest 12-month free cash flow is about $672.8 million, and a DCF model suggests intrinsic value aligns with the current price. The valuation hinges on whether medium-term cash flow expectations justify the market tag.American Banking and Market NewsMedpace Holdings, Inc. $MEDP Stock Sold by Boston Trust Walden CorpBoston Trust Walden Corp reduced its Medpace Holdings stake by 6.9% in Q3, selling 10,674 shares and leaving with 144,843 shares valued at $90.4 million. Insiders sold 342,647 shares in the last 90 days, and analysts rate the stock a Hold with a consensus price target of $649.27.Yahoo2 high-flying stocks on our watchlist and 1 we turn downStockStory highlights Inspire Medical Systems as a sell due to a 3.4% revenue decline and 52.2x forward P/E, while recommending Monolithic Power Systems and Medpace as buys with 35.9x and 35.7x forward P/E respectively. The article cites revenue growth and profitability for the recommended stocks.MarketBeat3,125 Medpace Holdings, Inc. $MEDP Shares Bought by North Dakota State Investment BoardNorth Dakota State Investment Board increased its Medpace Holdings stake by 470.6% in Q3, buying 3,125 shares to hold 3,789 shares worth $2.365 million. Medpace reported Q3 EPS of $4.84, beating estimates, with revenue of $716 million up 8.5% year-over-year. Analysts rate the stock a Hold with a consensus target of $649.27.